TOKYO -- Swiss pharmaceutical company Novartis has pegged its cancer-targeting radiopharmaceutical business as its next growth pillar, looking to make it "at least a $10 billion business" over the next decade, CEO Vasant Narasimhan told Nikkei in an interview.
Novartis spun off ophthalmology subsidiary Alcon in 2019 and generic drug subsidiary Sandoz in 2023, and announced plans to focus on advanced original drugs in areas like oncology.
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
